Bristol-Myers Squibb
Bristol Myers Squibb to acquire RayzeBio for $4.1 billion in cash
31 Dec 2023
American multinational pharmaceutical company Bristol Myers Squibb on Tuesday said it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business
Bristol-Myers to acquire Celgene in $74-bn cash-and-stock deal
03 Jan 2019
Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 per cent to Celgene’s Wednesday close, besides one tradable contingent value right for each share held
GlaxoSmithKline’s majority-owned HIV business to buy drugs from US rival Bristol-Myers Squibb
18 Dec 2015
Drugmaker Bristol-Myers Squibb acquires rights to Promedior Inc and its experimental drug PRM-151
01 Sep 2015
Health ministry seeks compulsory licence for Bristol-Myers' cancer drug
03 Apr 2014
A month’s dosage of Bristol-Myers Squibb’s patented drug Dasatinib, which is sold under the brand name `Sprycel’, costs around Rs60,000
AstraZeneca to pay Bristol-Myers Squibb $135 mn more for Amylin drug rights
10 Aug 2012
AstraZeneca will pay the $135 million to Bristol-Myers Squibb after the anti-trust and other competition regulators approve the acquisition of Amylin
Bristol-Myers to acquire hepatitis C oral drug developer Inhibitex for $2.5 bn
09 Jan 2012
Bristol-Myers Squibb over the weekend said that it will buy Inhibitex Inc, for about $2.5 billion in cash in order to expand its broad hepatitis C portfolio
Bristol-Myers to divest Mead Johnson for $7.69 billion
16 Nov 2009
Leading maker of children's nutritional products, the over 100-year Mead Johnson had 2008 sales of nearly $2.6 billion
Sigma acquires Bristol-Myers Sqibb’s brands
07 Sep 2009
Bristol-Myers to acquire biotechnology company Medarex for $2.4 billion
23 Jul 2009
US drugmaker Bristol-Myers Squibb said yesterday that it is acquiring biotechnology company Medarex Inc, a for $2.4 billion to expand its oncology and immunology pipeline
Bristol-Myers, Syngene open new R&D facility
24 Mar 2009
ImClone rejects Bristol-Myers Squibb's $4.3 billion bid; cites $6.1 billion fresh offer
10 Sep 2008
Biotech company ImClone Systems has rejected Bristol-Myers Squibb's $4.3 billion bid as too low, saying it has received a higher offer from a large pharmaceutical company.
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
